Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?

The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database to study the associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thotamgari, Sahith Reddy, Grewal, Udhayvir Singh, Sheth, Aakash R., Babbili, Akhilesh, Dominic, Paari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187195/
https://www.ncbi.nlm.nih.gov/pubmed/35702660
http://dx.doi.org/10.1097/XCE.0000000000000265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187195/
https://www.ncbi.nlm.nih.gov/pubmed/35702660
http://dx.doi.org/10.1097/XCE.0000000000000265

Ejemplares similares